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Introduction
Since its discovery, vitamin B12 deficiency has been re-
ported to result in various neurological syndromes,
which include subacute combined degeneration (SCD),
peripheral neuropathy, dementia and psychiatric abnor-
malities [10, 16, 20, 23, 26]. In the West, B12 deficiency
neurological syndromes are reported mostly in patients
with pernicious anemia, elderly individuals and chil-
dren with an inherited defect in B12 metabolism [6,
8–10, 31]. Sensory motor dysfunctions in SCD have been
documented using nerve conduction and motor- and
sensory-evoked potentials [8, 16]. A subclinical visual
pathway abnormality has also been reported using vi-
sual evoked potential in 60 % of patients with B12 defi-
ciency neurological syndromes [18]. Cognitive impair-
ment has been reported in various early studies but
cognitive evoked potential changes and its response to
therapy have not been reported. In this communication,
we report the cognitive functions in patients with B12
deficiency neurological syndromes and their response
to therapy.
JO
N
 2660
■ Abstract Objective To evaluate
cognitive function in B12 defi-
ciency neurological syndromes and
response to B12 therapy. Methods
Patients were diagnosed on the
basis of low serum B12 or mega-
loblastic bone marrow or both.
Detailed neurological examination
was performed and mental status
was evaluated by the Mini Mental
State Examination (MMSE). Hemo-
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globin, RBC indices, blood counts,
serum chemistry, HIV, thyroid pro-
file, antiparietal cell antibody and
craniospinal MRI were done. Cog-
nitive evoked potential was carried
out using the odd ball auditory
paradigm and recording was
achieved from Fz, Cz and Pz re-
ferred to mastoid. P3 latency and
amplitude were measured and
compared with 33 age and sex
matched controls. Three months
following B12 therapy, clinical and
P3 values were reevaluated and
compared with the baseline values.
Results 36 patients, aged 16–80
years were included; 32 patients
were above 40 years of age. Their
median education level was 14
years. The presenting syndrome
was myeloneurocognitive in 9,
myeloneuropathy in 10, myelocog-
nitive in 8, myelopathy in 8 and
only cognitive in 1 patient. MMSE
was abnormal in 17; between 28–19
in 14 and 18–11 in 3 patients. Cra-
nial MRI carried out in 14 patients
revealed multiple white matter hy-
perintensity in T2 in 3 and cortical
atrophy in 1. P3 was unrecordable
in 7 and latency was prolonged in 8
out of 33 patients. P3 latency was
significantly prolonged in patients
compared to controls and both
MMSE and P3 latency improved
significantly at the 3-month follow-
up. Conclusion MMSE was abnor-
mal in 47 % and P3 in 45.5 % of pa-
tients with B12 deficiency
neurological syndromes which im-
proved following treatment. Signif-
icance There is high incidence of
reversible cognitive impairment
and P3 abnormalities in B12 defi-
ciency neurological syndromes.
■ Key words subacute combined
degeneration · B12 · dementia · P3 ·
MRI · outcome
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Patients and methods
From 2004 to 2005, 36 patients with B12 deficiency neurological syn-
dromes, who were referred to us, were included in this study. The
diagnosis of B12 deficiency was based on low serum B12 (< 211
pg/ml) and or megaloblastic bone marrow.A detailed medical history
including dietary habit, daily intake of milk or its product, malab-
sorption syndrome, addiction, gastrointestinal surgery and hepatic
and renal failure were noted. Cognitive function was evaluated by the
Mini Mental State Examination (MMSE). Patients were considered
cognitively impaired if MMSE was below 29 for 9 years of schooling,
below 26 for 5–8 years of schooling and below 22 for 0–4 years of
schooling [7].Visual functions were assessed by field,color and acuity
of vision.Presence of optic atrophy and other cranial nerve palsy were
noted. Muscle power was assessed by the MRC (Medical Research
Council) scale, muscle tone, reflex and sense of joint position, touch
and pinprick were also noted.
The laboratory investigations included hemoglobin, RBC indices,
leukocyte counts, platelet, RBC morphology and segmented poly-
morph. Blood sugar (fasting and post prandial), serum bilirubin,
transaminases, lactate dehydrogenase, protein, albumin, creatinine,
blood urea nitrogen, thyroid profile and HIV serology were measured
in all patients.Fasting blood was centrifuged and serum was analyzed
for B12 using ADVIA Centaur assay (Bayer Corporation), which is a
competitive immunoassay using direct chemiluminescence technol-
ogy. Antiparietal cell antibody was assessed using the enzyme linked
immunosorbent assay. Bone marrow aspirate was obtained by sternal
puncture and examined for any abnormality.
Cervicodorsal spinal MRI was carried out using 1.5 T signa GE
medical system, USA and T1, T2 and fast spin echo T2 images were
obtained in the sagittal and axial views. In some patients cranial MRI
was also carried out.
■ Cognitive evoked potential
For cognitive evoked potential the stimuli were delivered using the
auditory oddball paradigm where two types of tones – target (rare)
and non-target (frequent) – were used at a rate of 1 Hz which was de-
livered binaurally. The target tones comprised of 20 % of total stimuli,
which appeared randomly. The patient was asked to count the target
tones mentally.The stimulus (tone) intensity was kept between 60 and
80 dBSPL depending on the tolerance of the individual. The low-fre-
quency responses extended to below 1 Hz and the high frequency re-
sponse to above 30 Hz. The sweep time was 1 s. A total of 32 rare
epochs were averaged. The recording electrodes were placed at Fz, Cz
and Pz referred to linked mastoids. The impedance was kept below 5
KΩ, sweep 100 ms/div with sensitivity 20 μv/div. The P3 responses
were averaged twice for reproducibility. The peak latency of N1, P2,
N2 and P3 and their peak to peak amplitudes were measured in Fz, Cz
and Pz channels averaging the infrequent stimuli [15]. The abnor-
malities were defined on the basis of mean ± 2.5 SD of controls which
were obtained from 33 healthy age (43.61 ± 14.74) and sex matched
volunteers. The upper limit of latency of CzP3 was 397.92
(338.30 ± 23.85) ms, FzP3396.53 (338.26 ± 23.31) ms and PzP3418.26
(342.14 ± 30.45) ms. The amplitudes had a wide normal distribution;
therefore, it was not considered for defining abnormality.
Patients were treated with vitamin B12 injection 1000 μg daily for
10 days, alternate day for 10 injections, weekly for 1 month then
monthly. At 3 months, the patients were evaluated clinically and cog-
nitive evoked potentials were repeated. The functional outcome was
defined as complete (independent for activities of daily living), par-
tial (dependent for activities of daily living) and poor (bed ridden)
[16].
■ Statistical analysis
The P3 parameters were compared with the controls and patients
with abnormal MMSE with normal MMSE using independent t test.
The base line and 3-month MMSE and P3 were compared by paired t
test. The correlation of P3 with various clinical, radiological and lab-
oratory parameters were evaluated by using parametric or nonpara-
metric test with the help of SPSS 10 software.
Results
A total of 36 patients with B12 deficiency neurological
syndromes were included with 8 being female. The
mean age of the patients was 50.6 (16–80) years; 32 pa-
tients were above the age of 40 years and 3 between 25
and 40 years. The mean duration of illness was 11.4
(0.25–50) months. Their median education level was 14
(2–17) years. 31 patients were vegetarian and 2 occa-
sional non-vegetarian (< 1/week); only 4 of these pa-
tients consumed milk > 500 ml/day. None of the patients
was in a retirement home or living alone. None had gas-
trointestinal surgery, malabsorption or HIV. Two pa-
tients had hepatitis and 2 consumed alcohol
(100–500 ml/day). One patient had vitiligo but none had
thyroid dysfunction or rheumatoid arthritis. The serum
vitamin B12 level was low in 30 out of 34 and mega-
loblastic bone marrow in all 20 patients in whom it was
carried out. Four patients with a normal B12 level, how-
ever, had megaloblastic bone marrow. Antiparietal cell
antibody was present in 50 % of patients.
The presenting syndromes at admission were
myeloneuropathy with cognitive impairment in 9,
myeloneuropathy in 10, myelocognitive in 8, myelopathy
in 8 and only cognitive impairment in one patient.15 pa-
tients complained about memory impairment and 17
had a low MMSE score with regard to their education
and age cutoff. Dementia was mild to moderate. The
MMSE score was 28–19 in 14 and 18–11 in 3 patients. On
the basis of MMSE, the majority of these patients had
impaired recall [14] and serial 7s [17] which is a bedside
test primarily of attention. Disorientation to time was
present in 7 and person in 5, impaired naming in 9, writ-
ing in 4 and coping in 2 patients.
■ Behavioral abnormalities
Behavioral abnormalities in the form of aggression,
rigidity of thoughts, anxiety, visual hallucination and
delusion were the dominant feature in 5 patients. Para-
noid delusion was present in 1 patient, delusion of
grandiosity in 2 and delusion of reference in 1. Two pa-
tients were treated as schizophrenia due to psychosis,
hallucination and flight of ideas.One patient was treated
as diffuse Lewy body disease due to hallucination, fluc-
tuating consciousness and associated akinetic rigid
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state. All these patients had associated features of
myeloneuropathy except one.
None of the patients had optic atrophy or visual ab-
normality. Lower limb weakness was severe (grade 0-I)
in 1, moderate (grade II-III) in 3, mild (grade IV) in 10
and the remaining patients had normal muscle power.
Knee reflex was brisk in 28 and reduced in 6 patients.
Ankle reflex was absent in 19 patients. Lower limb joint
position and vibration was impaired in all except one
and 2 patients had horizontal level (C4 and D10 spinal
level) of sensory loss.
Twenty patients were anemic (Hb < 12 g/dl) and
mean corpuscular volume was increased in 25; 5 of
whom had segmented polymorph. Serum albumin was
low in 6 and raised lactate dehydrogenase in 14/21pa-
tients.
MRI was performed in 24 patients. Spinal MRI re-
vealed T2 hyperintensity of cervicodorsal region and
cord atrophy in 11 patients each out of 24 patients.Three
patients also had multiple cervical disc protrusion with
thecal indentation only. Cranial MRI was also done in 14
patients and revealed multiple T2 hyperintense lesions
in 3 (Fig. 1) and diffuse cortical atrophy in 1 patient. One
patient, who had an old cerebellar stroke, was hyperten-
sive.
■ Cognitive evoked potential
Cognitive evoked potential was carried out in 33 pa-
tients and it was unrecordable in 7 and had a prolonged
CzP3 latency in 8 patients. P3 latency and MMSE were
significantly abnormal in patients compared to controls
(Table 1); however, amplitudes were not significantly
different. Patients with abnormal MMSE had more pro-
longed P3 latency (417.58 ± 62.31 ms) compared to nor-
mal MMSE (369.29 ± 27.16 ms) which is significant
(t = 2.49, p = 0.03). Cz P3 amplitude however was not sta-
tistically different (t = –0.08, P = 0.93) between abnorm-
al MMSE (14.72 ± 5.90μv) and normal (14.90 ± 5.28μv).
CzP3 latency correlated with age (P = 0.04), hemoglobin
(0.004),MCV (0.0001),MMSE (P = 0.02) but not with du-
ration of illness (P = 0.94), presenting syndrome
(P = 0.07) or antiparietal cell antibody (P = 0.29).Abnor-
mality in cranial MRI in the form of cortical atrophy and
white matter changes did not correlate with MMSE
(P = 1.00) or P3 abnormality (P = 0.30). Peroneal and
sural nerve conductions were measured in 33 patients
and were abnormal in 7 patients.P3 abnormality did not
correlate with nerve conduction abnormality (P = 0.39).
■ Follow-up
A total of 31 patients were followed up at 3 months; 29
patients had complete and 2 had partial functional re-
covery. Lower limb power improved in all and joint po-
sition in 5 patients; however, reflex abnormality per-
sisted. Behavioral abnormality improved in all. MMSE
score improved in all and became normal in 29 patients.
The cognitive evoked potential was repeated in 18 pa-
tients and was recordable in 17 patients including 3 pa-
tients who had an initially unrecordable P3. P3 latency
was within the normal range in 15 (Fig. 2) and pro-
longed in 2 patients. There was a significant improve-
ment in MMSE and P3 latency at the 3-month follow-up
compared to base line (Table 2). The details of clinical
presentation, hemoglobin level, MMSE score and CzP3
latency are summarized in Table 3.
Discussion
In our study cognitive impairment was found in 47.2 %
of patients with vitamin B12 deficiency neurological
syndrome and 45.5 % had abnormal cognitive evoked
potential. Cognitive abnormality has been reported to
Fig. 1 Cranial MRI, T2 sequence of a patient with B12 deficiency neurological syn-
drome revealed multiple white matter hyperintensity
Table 1 Comparison of P3 and MMSE changes in patients with B12 deficiency
neurological syndromes (SCD) and controls
Parameters SCD (n = 26) Normal (n = 33) P value
CzP3
Latency ms 391.58 + 51.91 338.30 ± 23.85 0.0001
Amplitude μv 14.82 + 5.46 13.23 ± 6.79 0.33
FzP3
Latency ms 390.81 ± 48.59 338.26 ± 23.31 0.0001
Amplitude μv 14.14 ± 6.62 13.23 ± 6.79 0.61
PzP3
Latency ms 393.16 ± 57.03 342.15 ± 30.45 0.0001
Amplitude μv 14.28 ± 4.45 14.27 ± 6.68 0.99
Age 50.56 ± 15.09 43.61 ± 14.74 0.06
MMSE 27.03 ± 4.40 28.94 ± 1.43 0.02
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be rare. In a large study of 143 patients with cobalamin
deficiency, only 8 % of patients had cognitive impair-
ment. The lower frequency of cognitive impairment in
the earlier study may be due to different patient popula-
tions, inclusion of milder cases, and lack of quantitative
mental status evaluation. An elderly population survey
however revealed a high prevalence of cobalamin defi-
ciency which was associated with reduced MMSE and
behavioral abnormality [6]. In a patient with B12 defi-
ciency due to pernicious anemia, detailed evaluation of
cognitive functions using extensive protocol revealed
multifocal cognitive impairments affecting, in particu-
lar, intellectual function, memory, word retrieval and
problem solving skills [13]. Cognitive abnormality in
our patients was mostly global with frequent abnormal-
ities in attention as assessed by serial 7s, orientation,
naming and recall simulating Alzheimer’s disease. The
B12 deficiency dementia however can be differentiated
from Alzheimer’s disease by its rapidity of progression,
associated myelo- or myeloneuropathy and improve-
ment of cognitive functions following B12 therapy.
Rapidly progressive cognitive impairment, myelopathy
and cranial MRI abnormalities found in our patients
simulated HIV encephalomyelopathy. The myelopathy
in HIV clinically and pathologically simulate subacute
combined degeneration as both produce patchy or dif-
fuse vacuolar demyelination affecting posterior and
pyramidal tract [4]. Subcortical white matter T2 hyper-
intensity followed by cortical atrophy has been de-
scribed in HIV encephalopathy. HIV virus affects oligo-
dendroglia resulting in demyelination, inflammatory
changes and astrocytosis [14]. In subacute combined
degeneration, small ill-defined often perivascular foci of
demyelination within the cerebral white matter have
been described. Histopathologically there is fusiform
swelling of the myelin sheath and axons in newer foci
and fiber degeneration in older foci [1]. Neurons and
oligodendroglia are spared but there are astrocytosis
and myelinolysis due to the cobalamin dependent enzy-
matic pathway [12]. Recently increased TNFα and re-
duction of neurotrophic factors IL6 and EGF have been
suggested for CNS damage in subacute combined de-
generation [24]. All our patients were negative for HIV
and they improved following B12 therapy. The associa-
tion of B12 deficiency in various neurological diseases
such as multiple sclerosis [19], Alzheimer’s disease [30]
and HIV [4] although postulated have yet to be con-
firmed in view of a lack of improvement following B12
therapy. Routine measure of cognitive function by
MMSE often fails to detect executive cognitive dysfunc-
tion; moreover MMSE is education and age dependent
[22]. In our study lack of detailed cognitive functions
evaluation may miss mild cognitive impairment. MMSE
with the clock drawing or short performance test is
found to be more sensitive for detecting cognitive dys-
Fig. 2 Cognitive evoked potential of the same pa-
tient showing prolonged P3 latency which improved
the 3-month B12 therapy. His MMSE score also im-
proved from 23 to 30. F frequent stimuli
Initial
F
Fz-M1M2
P3=450ms
Cz-M1M2
Pz-M1M2
Rare
F
Rare
F
Rare
3 mo
Fz-M1M2
P3=300ms
Pz-M1M2
20 uv
100ms
Cz-M1M2
F
Rare
F
Rare
F
Rare
Table 2 Comparison of baseline and 3 months follow-up P3 and MMSE changes
in patients with B12 deficiency neurological syndromes
Parameters Initial 3 mo p value
CzP3
Lat ms 376.38 ± 55.72 329.08 ± 41.84 0.004
Ampl μv 15.26 ± 6.92 16.61 ± 6.64 0.60
FzP3
Lat ms 372.15 ± 46.11 327.46 ± 33.44 0.004
Ampl μv 14.15 ± 6.20 15.08 ± 8.25 0.71
PzP3
Lat ms 374.42 ± 65.08 337.67 ± 37.49 0.006
Ampl μv 13.58 ± 5.35 15.45 ± 6.35 0.38
MMSE 28.16 ± 2.98 29.68 ± 1.19 0.006
Lat latency; Ampl amplitude
353_000_Kalita_JON_2660  14.03.2008  8:07 Uhr  Seite 356
357
function [3,25].Use of age and education-specific cut off
scores, however improves the sensitivity of MMSE to
82 % with no loss of specificity [27]. We have also used
age and education cut off.
Spinal MRI frequently shows posterior hyperinten-
sity and cord atrophy [2, 16], but there is paucity of cra-
nial MRI study in B12 deficiency syndromes and cranial
involvement has been thought to be rare [10]. White
matter changes simulating leukoencephalopathy have
been reported in children with an inherited cobalamin
related co-enzyme defect [5, 21]. MRI abnormality sug-
gestive of delayed myelination has also been reported in
infants with nutritional cobalamin deficiency [29].
Spinal MRI changes in our study were consistent with
earlier reports [2, 16]. Cranial MRI revealed subcortical
white matter hyperintensity in T2 in 3 and cortical atro-
phy in one out of 14 patients. These changes are also de-
scribed in elderly,hypertensive and diabetic individuals.
None of these four patients were hypertensive or dia-
betic and 3 were below 60 years of age. Being able to
show the reversibility of MRI changes following therapy
however would have been helpful, but were not carried
out due to financial reasons.
In a large study on cobalamin deficiency, cognitive
impairment was found in 17 out of 153 episodes which
was characterized by global dementia in 8 and predom-
inant recent memory loss with reduced attention in 9.
Five of these episodes were associated with behavioral
abnormalities in the form of depression in 2,agitation in
2 and hypomimia in 1 [10]. In our study behavioral ab-
normalities were also present in 5 patients.Various psy-
chiatric abnormalities have been reported in earlier
Serial Age Clinical syndromes Hemoglobin Initial Follow-up Initial Follow-up
Number Years g/dl CzP3L ms CzP3L ms MMSE MMSE
1 80 Myeloneurocognitive 11.1 523 . 21 .
2 73 Myeloneuropathy 13.3 389 . 27 27
3 69 Myeloneurocognitive 11.8 NR . 29 29
4 68 Myeloneurocognitive 9.8 396 . 13 .
5 67 Myelopathy 12.1 380 374 30 30
6 67 Myelocognitive 9.8 450 . 28 .
7 62 Myeloneuropathy 11.3 NR 336 28 30
8 62 Myelopathy 11.5 364 340 30 30
9 61 Myelopathy 12 367 . 30 30
10 60 Myeloneuropathy 11 358 347 29 30
11 58 Myeloneuropathy 12.9 . . 28 30
12 58 Myeloneurocognitive 9.2 402 268 30 30
13 58 Myelocognitive 13.8 325 333 30 30
14 57 Myeloneurocognitive 6 NR NR 23 24
15 57 Cognitive 15.7 NR . 17 .
16 55 Myeloneuropathy 10.5 392 . 30 30
17 55 Myeloneuropathy 9.5 412 348 30 30
18 53 Myeloneurocognitive 11 526 430 27 30
19 53 Myelopathy 13.2 396 . 21 .
20 51 Myelocognitive 14.1 NR 408 30 30
21 51 Myelocognitive 14.1 . 387 29 30
22 50 Myeloneurocognitive 13 309 297 27 30
23 50 Myelopathy 9.7 441 . 28 30
24 49 Myelocognitive 13.5 388 . 30 30
25 45 Myeloneurocognitive 11.9 . . 30 30
26 43 Myeloneuropathy 10.5 404 297 23 30
27 42 Myelocognitive 9.2 430 . 23 30
28 40 Myelopathy 9 391 290 30 30
29 40 Myelocognitive 7.8 375 . 30 30
30 35 Myelocognitive 12.3 389 . 28 30
31 33 Myelopathy 12.2 330 323 30 30
32 31 Myelopathy 14.4 334 327 30 30
33 27 Myeloneurocognitive 8.2 NR . 17 30
34 25 Myeloneuropathy 12.3 NR 311 30 30
35 20 Myeloneuropathy 11 352 . 30 30
36 16 Myeloneuropathy 12.2 358 304 27 30
NR not recordable; L latency
Table 3 Clinical, Mini Mental State Ex-
amination (MMSE) and CzP3 latency be-
fore and 3 months after the treatment of
the patients with B12 deficiency neuro-
logical syndromes
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studies but detailed cognitive function and neurological
evaluations have not been done [11].
The role of the cognitive evoked potential has been
evaluated in various types of dementia and has been
found to be useful in monitoring the effect of therapy
[28]. P3 latency in our study was prolonged in patients
compared to controls and patients with abnormal
MMSE had greater prolongation than normal MMSE.
After B12 therapy all patients had a normal MMSE at the
3-month follow-up except 2. This was associated with
the corresponding improvement in P3 latency. The
mechanism of improvement in memory functions is not
clearly understood but may be related to improvement
in the cobalamin dependent metabolic pathway. The P3
latency correlated with age, duration of illness, MMSE,
Hb and MCV. Effect of age in P3 latency was reported in
an earlier study [17]. We have therefore selected an age
matched control and serial follow-up study to reduce the
influence of age. B12 deficiency commonly occurs in
middle aged and elderly individuals, which may be due
to impaired absorptive and metabolic functions of B12
with age and compromised CNS function in the elderly.
Increased duration of illness, reduced hemoglobin and
increased MCV not only suggest more severe deficit but
also may contribute reduced cellular oxygenation.
It can be concluded from this study that mild to mod-
erate reversible cognitive impairment occurred in
47.2 % of patients and P3 was helpful in documenting
and monitoring the therapeutic response. Associated
myelo- or myeloneuropathy was the rule and cognitive
functions improved following B12 therapy.Abnormal P3
may help to discriminate cognitive impairment attribut-
able to B12 deficiency from coincident causes of cogni-
tive decline, though this would need to be tested in fu-
ture work.
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